Interventions for Tuberculosis Control and Elimination 2002

619. World Health Organization. The WHO/IUATLD Global Project on Anti-
Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in
the world. Report No. 2 - prevalence and trends. WHO/CDC/TB/2000.278:
Geneva: WHO, 2000; 1-253.
620. Lan NTN, Iademarco MF, Binkin NJ, Quy HT, Cô NV. A case series: initial
outcome of persons with multidrug-resistant tuberculosis after treatment with the
WHO standard retreatment regimen in Ho Chi Minh City, Vietnam. Int J Tuberc
Lung Dis 2001; 5: 575-8.
621. Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F,
Cohn DL, Lambregts-van Weezenbeek CSB, Kim SJ, Chaulet P, Nunn P. Global
surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998;
338: 1641-9.
622. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S,
Rieder HL, Binkin N, Dye C, Williams R, Raviglione MC. Global trends in
resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-303.
623. Pfyffer GE, Bonato DA, Ebrahimzadeh A, Gross W, Hotaling J, Kornblum J,
Laszlo A, Roberts G, Salfinger M, Wittwer F, Siddiqi S. Multicenter laboratory
validation of susceptibility testing of Mycobacterium tuberculosis against classical
second-line and newer antimicrobial drugs using the radiometric BACTEC
460 technique and the proportion method with solid media. J Clin Microbiol
1999; 37: 3179-86.
624. Bastian I, Rigouts L, Van Deun A, Portaels F. Directly observed treatment,
short-course strategy and multidrug-resistant tuberculosis: are any modifications
required? Bull World Health Organ 2000; 78: 238-51.
625. Grimaldo ER, Tupasi TE, Rivera AB, Quelapio MID, Cardaño RC, Derilo JO,
Velen VA. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant
Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital
in the Philippines. Int J Tuberc Lung Dis 2001; 5: 546-50.
626. Bechan S, Connolly C, Short GM, Standing E, Wilkinson D. Directly observed
therapy for tuberculosis given twice weekly in the workplace in urban South
Africa. Trans R Soc Trop Med Hyg 1997; 91: 704-7.
627. Sbarbaro JA. Compliance: inducements and enforcements. Chest 1979; 76(suppl):
750-6.
628. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an
idea. Lancet 1995; 345: 1545-8.
629. Snider DE, Hutton MD. Improving patient compliance in tuberculosis treatment
programs. U.S. Public Health Service, 1986.
630. Walley JD, Khan MA, Newell JN, Khan MH. Effectiveness of the direct observation
components of DOTS for tuberculosis: a randomised controlled trial in
Pakistan. Lancet 2001; 357: 664-9.
211